Forest Licenses Novexel’s Novel Broad-Spectrum Beta-Lactamase Inhibitor

By Business Review Editor

Pharma Deals Review: Vol 2008 Issue 93 (Table of Contents)

Published: 8 Mar-2008

DOI: 10.3833/pdr.v2008.i93.210     ISSN: 1756-7874

Section: Licensing



Novexel and Forest Laboratories Holdings entered into licensing agreement to develop, manufacture and commercialize Novexel’s intravenous beta-lactamase inhibitor, NXL104, in combination with Forest’s ceftraroline, an injectable broad-spectrum cephalosporin active against MRSA and multi-drug resistant Streptococcus pneumoniae...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details